Chief Executive Officer
Nikolaj Sørensen (born 1972) joined Orexo in 2011. He has an M.Sc. Business and Economics. His previous appointments include International commercial experience of the pharmaceuticals industry from Pfizer and Boston Consulting Group (BCG). He was a board member of the Swedish Pharmaceutical Industry Association (LIF). Mr Sørensen holds 16,770 shares and stock options entitling to 110,000 shares.